Zydus Lifesciences Limited has informed the Exchange about General Updates
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zydus Lifesciences' US subsidiary, Zydus Pharmaceuticals USA Inc. (ZPUI), has incorporated a new wholly owned subsidiary called Zylidac Bio LLC in the USA on July 11, 2025. This new entity has been set up specifically to acquire the two U.S.-based biologics manufacturing facilities of Agenus Inc., located in Emeryville, CA and Berkeley, CA. The move follows the earlier intimation dated June 3, 2025, where ZPUI signed a definitive agreement with Agenus to acquire these assets. Zylidac Bio LLC is yet to commence business operations, has no turnover, and was incorporated as an LLC without any initial share capital. The transaction is a related party transaction as the new entity is a step-down wholly owned subsidiary of Zydus.
This is a procedural step towards completing the previously announced acquisition of Agenus' biologics manufacturing assets, signalling progress on Zydus' strategic move to expand its biologics manufacturing footprint in the US. The new wholly owned subsidiary structure helps ring-fence the acquired assets, but the financial impact on shareholders will depend on the final deal value and how the acquired facilities contribute to revenue and margins going forward.